spironolactone has been researched along with Diabetic Angiopathies in 11 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The role of spironolactone as pemphigoid-inducing agent has recently been suggested." | 7.71 | [Bullous pemphigoid induced by spironolactone]. ( Cordel, N; Courville, P; Gilbert, D; Joly, P; Lauret, P; Modeste, AB, 2002) |
| "Ten patients with type II diabetes and hypertension were enrolled in a randomized, double-blind crossover study comparing 4 months' treatment with spironolactone and placebo with a 4-week washout phase." | 5.11 | Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients. ( Band, M; Davies, J; Gavin, A; Morris, A; Struthers, A, 2005) |
| "In the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial, hospitalized AMI patients complicated by left ventricular ejection fraction ≤40% and symptoms of HF receiving standard therapy were randomized 3-14 days post-AMI to receive eplerenone 25-50 mg/day (n = 3319) or placebo (n = 3313)." | 3.77 | Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. ( Aban, IB; Ahmed, A; Ahmed, MI; Deedwania, PC; Feller, MA; Love, TE; Pitt, B, 2011) |
| "The role of spironolactone as pemphigoid-inducing agent has recently been suggested." | 3.71 | [Bullous pemphigoid induced by spironolactone]. ( Cordel, N; Courville, P; Gilbert, D; Joly, P; Lauret, P; Modeste, AB, 2002) |
| "Treatment with spironolactone improved coronary microvascular function, raising the possibility that MR blockade could have beneficial effects in preventing cardiovascular disease in patients with T2DM." | 2.80 | Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. ( Adler, GK; Baimas-George, M; Di Carli, MF; Foster, C; Garg, R; Hurwitz, S; Jerosch-Herold, M; Kwong, RY; Rao, AD; Shah, RV, 2015) |
| " Our results showed a marked increase in aortic malondialdehyde (MDA) level and upregulation of the catalytic NADPH oxidase subunit, NOX2 gene expression alongside reducing catalase enzyme capacity, and the serum nitric oxide (NO) bioavailability in diabetic rats." | 1.40 | Spironolactone improves endothelial dysfunction in streptozotocin-induced diabetic rats. ( Adel, H; Khalifa, MM; Taye, A, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rajagopalan, S | 1 |
| Alaiti, MA | 1 |
| Broadwater, K | 1 |
| Goud, A | 1 |
| Gaztanaga, J | 1 |
| Connelly, K | 1 |
| Fares, A | 1 |
| Shirazian, S | 1 |
| Kreatsoulas, C | 1 |
| Farkouh, M | 1 |
| Dobre, M | 1 |
| Fink, JC | 1 |
| Weir, MR | 1 |
| Brown, SM | 1 |
| Meuth, AI | 1 |
| Davis, JW | 1 |
| Rector, RS | 1 |
| Bender, SB | 2 |
| Garg, R | 1 |
| Rao, AD | 1 |
| Baimas-George, M | 1 |
| Hurwitz, S | 1 |
| Foster, C | 1 |
| Shah, RV | 1 |
| Jerosch-Herold, M | 1 |
| Kwong, RY | 1 |
| Di Carli, MF | 1 |
| Adler, GK | 1 |
| Adel, H | 1 |
| Taye, A | 1 |
| Khalifa, MM | 1 |
| Jia, G | 1 |
| Sowers, JR | 1 |
| Deedwania, PC | 1 |
| Ahmed, MI | 1 |
| Feller, MA | 1 |
| Aban, IB | 1 |
| Love, TE | 1 |
| Pitt, B | 1 |
| Ahmed, A | 1 |
| Davies, JI | 1 |
| Band, M | 2 |
| Morris, A | 2 |
| Struthers, AD | 1 |
| Davies, J | 1 |
| Gavin, A | 1 |
| Struthers, A | 1 |
| Karagiannis, A | 1 |
| Tziomalos, K | 1 |
| Dona, K | 1 |
| Pyrpasopoulou, A | 1 |
| Kartali, N | 1 |
| Athyros, V | 1 |
| Zamboulis, C | 1 |
| Modeste, AB | 1 |
| Cordel, N | 1 |
| Courville, P | 1 |
| Gilbert, D | 1 |
| Lauret, P | 1 |
| Joly, P | 1 |
| Wolf, LM | 1 |
| Courtois, H | 1 |
| Schrub, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease[NCT00865124] | 69 participants (Actual) | Interventional | 2008-09-30 | Completed | |||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Coronary flow reserve (CFR), or myocardial perfusion reserve, was assessed via cardiac positron emission tomography (PET). CFR is the ratio of adenosine-stimulated blood flow through myocardium to resting blood flow through myocardium. An improvement in coronary flow reserve is beneficial. (NCT00865124)
Timeframe: Baseline and six months
| Intervention | ratio (Mean) |
|---|---|
| Spironolactone (MR Blockade) | 0.33 |
| Hydrochlorothiazide + Potassium | -0.10 |
| Placebo | 0.02 |
Diastolic function was assessed via tissue doppler imaging (TDI) by echocardiography to determine left ventricular diastolic function before and after 6 months of treatment. (NCT00865124)
Timeframe: Baseline and six months
| Intervention | ratio (Mean) |
|---|---|
| Spironolactone (MR Blockade) | 0.02 |
| Hydrochlorothiazide + Potassium | 0.06 |
| Placebo | 0.64 |
Renal vasculature was assessed by examining renal plasma flow, or para-aminohippurate (PAH) clearance, basally and in response to acute administration (3 nanograms/kg/min for 60 min) of the vasoactive agent, Angiotensin II. (NCT00865124)
Timeframe: Baseline and six months
| Intervention | mL/min/1.73m^2 (Mean) | |||
|---|---|---|---|---|
| Pre-treatment, PAH clearance, baseline | Pre-treatment, PAH clearance, Post-ANGII | 6 months post-treatment, PAH clearance, baseline | 6 months post-treatment, PAH clearance, Post-ANGII | |
| Hydrochlorothiazide + Potassium | 508 | 417 | 500 | 415 |
| Placebo | 518 | 436 | 491 | 427 |
| Spironolactone (MR Blockade) | 527 | 442 | 518 | 423 |
Diastolic function was assessed via tissue doppler imaging (TDI) by echocardiography to determine left ventricular diastolic function before and after 6 months of treatment; and in response to acute administration (3 nanograms/kg/min for 60 min) of the vasoactive agent, Angiotensin II. (NCT00865124)
Timeframe: Baseline and six months
| Intervention | ratio (Mean) | |||
|---|---|---|---|---|
| Pre-treatment, E/e', baseline | Pre-treatment, E/e', Post-ANGII | 6 months post-treatment, E/e', baseline | 6 months post-treatment, E/e', Post-ANGII | |
| Hydrochlorothiazide + Potassium | 6.72 | 7.06 | 7.03 | 5.83 |
| Placebo | 6.55 | 6.70 | 7.35 | 7.48 |
| Spironolactone (MR Blockade) | 6.67 | 7.09 | 6.76 | 6.28 |
4 trials available for spironolactone and Diabetic Angiopathies
| Article | Year |
|---|---|
Design of the Magnetic Resonance Imaging Evaluation of Mineralocorticoid Receptor Antagonism in Diabetic Atherosclerosis (MAGMA) Trial.
Topics: Aorta, Thoracic; Aortic Diseases; Atherosclerosis; Clinical Protocols; Diabetes Mellitus, Type 2; Di | 2017 |
Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Circulation; Diabetes Mellitus, Type | 2015 |
Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Circulation; Diabetes Mellitus, Type | 2015 |
Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Circulation; Diabetes Mellitus, Type | 2015 |
Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Coronary Circulation; Diabetes Mellitus, Type | 2015 |
Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diabetic Angiopath | 2004 |
Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients.
Topics: Aged; Blood Flow Velocity; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic A | 2005 |
7 other studies available for spironolactone and Diabetic Angiopathies
| Article | Year |
|---|---|
Mineralocorticoid receptor antagonism reverses diabetes-related coronary vasodilator dysfunction: A unique vascular transcriptomic signature.
Topics: Animals; Arterioles; Coronary Artery Disease; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic | 2018 |
Spironolactone improves endothelial dysfunction in streptozotocin-induced diabetic rats.
Topics: Administration, Oral; Animals; Antioxidants; Aorta; Diabetes Mellitus, Experimental; Diabetic Angiop | 2014 |
Mineralocorticoid receptors: an appealing target to treat coronary microvascular dysfunction in diabetes.
Topics: Coronary Circulation; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Male; Microc | 2015 |
Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure.
Topics: Aged; Diabetic Angiopathies; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineraloc | 2011 |
Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient.
Topics: Adrenal Glands; Arteriosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; | 2005 |
[Bullous pemphigoid induced by spironolactone].
Topics: Aged; Biopsy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Eruptions; Drug Therapy, Combin | 2002 |
[Hypercalcemia and thiazides].
Topics: Benzothiadiazines; Diabetic Angiopathies; Diuretics; Drug Synergism; Edema; Female; Humans; Hypercal | 1973 |